In southern Taiwan, there is a significant outbreak of Dengue fever, with the number of infections surpassing twenty thousands of cases this year, reaching a new high for the same period in the past ten years according to statistics from the Centers for Disease Control (CDC). In order to overcome the challenges in treating Dengue fever, AMS BioteQ has devoted several years to figure out the hot potato. Recently, we’ve proudly announced that the drug candidate has significant inhibitory effects against the Dengue virus(DENV). In other words, we achieves milestone as Taiwan's first to develop Dengue Fever treatment!
Dr. George Tsai, AMS BioteQ Chairman stated that the company utilizes materials from medicinal fungi. After a series of extractions and isolations, the structure is fully identified. Through artificial synthesis, chemical compounds are produced based on the identified structure. Additionally, a series of methods, including freeze-drying, is employed to obtain freeze-dried materials. The collected compounds are then subjected to a series of tests in the biological cell laboratory. The small-molecule drugs of AMS BioteQ are synthetic compounds with a molecular weight below 500, and they possess the feature of being artificially synthesizable. These drugs can potentially be formulated for oral administration, making them more acceptable to various types of patients. The compounds, YUAN-01 and YUAN-03, owned by AMS BioteQ, are undergoing Dengue virus type 2 inhibition tests in laboratories in Taiwan and Thailand and the result confirms an impressive inhibitory effect. Currently, animal experiments are in progress, with the hope of announcing the results and advancing to the next stage of drug development.
▲▼Dr. George Tsai, AMS BioteQ Chairman stated that the company utilizes materials from medicinal fungi. After a series of procedure, the collected compounds are then subjected to some related tests in the biological cell laboratory, with a rigorous quality control process throughout the whole process.
Dr. George Tsai is personally involved in every aspect, putting himself in the frontline, whether the wound dressing development or antiviral drug research, we all achieve the breakthrough results. Through the in-house developed AI drug screening platform, which is accelerating the process of small molecule drug development and increasing the success rate of drug research. Dr. George Tsai mentioned that AMS BioteQ is collaborating with the Department of Chemistry research team at National Cheng Kung University to develop an AI drug screening platform. By adopting a reciprocal approach of "discover drugs for diseases" and "discover diseases for drugs," the platform addresses drug indications, chemical structures, and the contact points of drugs with proteins. This approach shortens the entire research and development process and reduces unnecessary expenses in the study. AMS BioteQ actively utilizes its unique technologies by collaborating with health authorities and NGO organizations worldwide to collectively tackle challenging public health issues.
▲AMS BioteQ is expected to collaborates with well-known foreign pharmaceutical companies and new drug development funds to develop Dengue fever drugs with greater economic scale, leading the company towards the next milestone!
AMS BioteQ collaborates with Kaohsiung Medical University and Thailand's Chulalongkorn University, combining the developed small molecule drugs with the antiviral drug screening platform. In the near future, we’ll be about to collaborate with well-known foreign pharmaceutical companies and new drug development funds to develop Dengue fever drugs with greater economic scale, giving back to society and leading the company towards the next milestone!